Target Name: CDC25B
NCBI ID: G994
Other Name(s): MPIP2_HUMAN | Cell division cycle 25B | CDC25HU2 | CDC25 homolog B | CDC25B variant 1 | Cell division cycle 25B, transcript variant 1 | CDC25B variant 3 | OTTHUMP00000030138 | cell division cycle 25B | CDC25B3 | Cell division cycle 25B, transcript variant 2 | Cell division cycle 25B, transcript variant 3 | M-phase inducer phosphatase 2 | CDC25B variant 2 | dual specificity phosphatase Cdc25B | M-phase inducer phosphatase 2 (isoform 3) | OTTHUMP00000030137 | Cell division cycle 25 B2 | M-phase inducer phosphatase 2 (isoform 2) | Dual specificity phosphatase Cdc25B | OTTHUMP00000030139 | Cell division cycle 25 B3 | CDC25B2 | M-phase inducer phosphatase 2 (isoform 1) | Cell division cycle 25B protein

CD25B: A Promising Drug Target and Biomarker for Multiple Sclerosis

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to a range of symptoms such as muscle weakness, numbness, and fatigue. The exact cause of MS is not known, but research has identified several factors that contribute to its development, including inflammation, genetic predisposition, and environmental triggers.

CD25B, a protein that is expressed in the immune cells, has been identified as a potential drug target and biomarker for MS. In this article, we will discuss the research on CD25B and its potential as a drug target and biomarker for MS.

CD25B: Structure and Function

CD25B is a cell surface protein that is expressed in the immune cells, including T-cells, NK cells, and B-cells. It is a member of the BCR/Abl family and is known as the CD25 antigen. CD25B is a 21- kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain.

CD25B functions as a receptor for the antigen CD21, which is a glycoprotein that is expressed in many tissues and cells, including the immune cells. When CD21 binds to CD25B, it triggers several signaling pathways that result in the activation and proliferation of immune cells.

CD25B has also been shown to play a role in the regulation of inflammation and immune cell function. Studies have shown that CD25B promotes the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12, and can inhibit the production of anti- -inflammatory cytokines, such as IL-10.

CD25B as a Drug Target

CD25B has been identified as a potential drug target for MS due to its role in the regulation of immune cell function and the development of multiple sclerosis. Several studies have shown that modulating CD25B activity can be an effective way to treat MS.

One of the main strategies for targeting CD25B is the use of small molecules that can modulate its activity. Several studies have shown that inhibitors of CD25B, such as pipeline compounds N-acyl-L-tryptophan (NALP) and 2-[(2- Methylpropyl)amino]-2-[(9H-fluorenylmethoxy)dimethyl]-pyrrolidone (FMOD), can effectively suppress the production of pro-inflammatory cytokines and improve immune cell function in MS patients.

In addition to inhibitors, CD25B has also been shown to be a potential target for protein kinase inhibitors. Several studies have shown that CD25B is a substrate for the protein kinase A, which is involved in the regulation of cell growth, differentiation, and inflammation.

CD25B as a Biomarker

CD25B has also been identified as a potential biomarker for MS. Several studies have shown that the level of CD25B is significantly increased in the blood and brain of MS patients compared to healthy individuals.

CD25B has been shown to be a reliable biomarker for monitoring disease activity in MS patients. Studies have shown that the level of CD25B is significantly correlated with the severity of MS symptoms, as well as the number of disease-modifying factors (DMFs) that are present in the blood.

Conclusion

CD25B is a protein that has been identified as a potential drug target and biomarker for MS. The evidence supports the use of small molecules and protein kinase inhibitors as

Protein Name: Cell Division Cycle 25B

Functions: Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity

More Common Targets

CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8